Skip to content

Overweight and Obesity in Adolescents - Sleep Behavioral Intervention

Treatment of Overweight and Obesity in Adolescents - Impact of a Sleep Behavioral Intervention - SLEEP-OB

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07255274
Acronym
SLEEP-OB
Enrollment
126
Registered
2025-12-01
Start date
2025-06-03
Completion date
2026-12-31
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and Overweight, Sleep Disorder

Keywords

Obesity, Sleep, Behavioral intervention, Adolescents

Brief summary

Sleep plays a crucial role in energy balance, alongside diet and physical activity. Research has linked poor sleep quality and short sleep duration to obesity and cardiometabolic risk, such as insulin resistance and hypertension. The nature of this association is complex, and several mechanims have been suggested. Scientific evidence suggests that sleep interventions may provide additional benefits in optimizing the effectiveness of overweight/obesity treatment in pediatric populations. Although some studies have explored this hypothesis, methodological heterogeneity hampers clear interpretation of the results. The main goal of this clinical trial is is to evaluate the efficacy of a sleep behavioral intervention, combined with standard obesity treatment, in reducing adiposity (measured by BMI z-score, fat mass percentage, or fat-free mass index) in adolescents with overweight or obesity. This randomized controlled trial will compare a control group receiving treatment as usual (or standard obesity treatment) with an intervention group receiving treatment as usual plus a sleep behavioral intervention. Participants will be randomized into two groups: intervention and control. Throughout the study period, all medical consultations will include standard interventions focused on nutrition, physical activity/sedentary behavior, and other lifestyle factors. The sleep-focused intervention will be delivered by psychologists. Participants will attend clinic visits every two months during the 6-month intervention period, and every three months during the subsequent 6-month follow-up period.

Detailed description

A randomized controlled trial (open-label, behavioral intervention) will be conducted at ULS Cova da Beira and Hospital CUF Porto, enrolling 126 adolescents (ages 13-17) diagnosed with overweight or obesity and poor sleep quality. Participants will be randomized into two groups: the intervention group (sleep behavioral intervention plus treatment as usual) and the control group (treatment as usual). In addition to the primary aim, the researchers will evaluate several secondary outcomes, including the efficacy of the intervention in relation to: cardiometabolic risk, sleep patterns, eating patterns, physical activity level, emotional well-being/self-compassion, quality of life, leptin and ghrelin levels, and tryptophan and melatonin metabolism. Throughout the study period, all medical consultations will include standard multicomponent behavioral intervention. The sleep behavioral intervention will be conducted by psychologists. The intervention consists of seven cognitive-behavioral therapy (CBT) sessions over six months, focusing on sleep hygiene, self-monitoring, stimulus control, cognitive therapy, and relaxation techniques. Data collection and analysis will include objective sleep assessment using actigraphy and a level 3 ambulatory sleep study. Blood samples will be collected at baseline, six months, and twelve months to analyze metabolic markers. From the samples collected at months 0 and 6, a portion will be appropriately stored for additional analysis at an external facility to quantify leptin, ghrelin, and tryptophan pathway metabolites. Anthropometric and clinical assessments will include measurements of body mass index (BMI), waist circumference, body composition, and blood pressure. Validated questionnaires will be used to evaluate sleep patterns, eating behaviors, physical activity, quality of life, emotional well-being, and self-compassion. It is anticipated that the sleep behavioral intervention combined with standard treatment will be more effective than standard treatment alone not only in reducing adiposity, but also in improving cardiometabolic risk, sleep patterns, eating patterns, physical activity, emotional well-being, self-compassion, and in regulating hormonal and metabolic pathways including ghrelin, leptin, and the tryptophan-melatonin axis, as outlined in the study hypotheses The study also aims to clarify the role of ghrelin and leptin levels, as well as the tryptophan pathway, in the interaction between sleep and obesity and in the effects of the intervention Emotional well-being and self-compassion are expected to mediate the response to obesity intervention and the sleep-obesity relationship, potentially influencing or influenced by the tryptophan metabolic pathway, particularly serotonin levels. By deepening the knowledge about the relationship between sleep and obesity, this research may contribute to optimize interventions for pediatric obesity, which would have an unequivocal positive impact.

Interventions

BEHAVIORALSleep Behavioral Intervention

Our research team, composed by pediatricians with experience in Obesity and Adolescent Medicine, and clinical psychologists with experience in Sleep, Obesity, and Cognitive Behavioral Therapy (CBT), developed a specific manual for this project: Behavioral Sleep Intervention - SLEEP-OB - Therapist Support Manual. The manual was adapted based on CBT models for adults and adolescents with insomnia and on CBT for adolescents with other sleep disorders and comorbidities, namely obesity. The behavioral intervention aims to promote sustainable changes in sleep. It includes behavioral strategies (such as sleep restriction, stimulus control), cognitive strategies (cognitive reappraisal/restructuring, cognitive control, paradoxical intention), mixed strategies (sleep education/hygiene, relaxation), self-monitoring, and problem identification and resolution. The intervention will take place over six months, with a total of seven sessions (in-person and by video call).

OTHERStandard Obesity Treatment

Standard obesity treatment for pediatric obesity according to international guidelines. It comprises pediatric appointments, and usually also nutrition and nursing appointments, every 2 to 3 months. These appointments include an anthropometric evaluation, physical examination and personalized multicomponent behavioral intervention with focus on nutrition, physical activity/sedentary behavior and other lifestyle recommendations. This standard intervention is common for both groups/arms.

Sponsors

University of Beira Interior
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Randomization is performed by a researcher not involved in data management.

Intervention model description

Open-Label Randomized Clinical Study with a Behavioral Intervention

Eligibility

Sex/Gender
ALL
Age
13 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

1. Informed consent from legal guardians and assent/consent from the adolescent; 2. Age between 13 and 17 years at the time of consent; 3. Diagnosis of overweight (BMI z-score \> 1 and ≤ 2) or obesity (BMI z-score \> 2), according to WHO criteria; 4. Sleep deprivation or poor sleep quality, based on the initial screening questionnaire.

Exclusion criteria

1. Secondary obesity (e.g., hypothalamic, genetic, or endocrine causes); 2. Comorbid psychiatric or neurological disorders (e.g., epilepsy, autism spectrum disorder) that affect sleep; 3. Current treatment with selective serotonin reuptake inhibitors (SSRIs) or other medications affecting sleep.

Design outcomes

Primary

MeasureTime frameDescription
Fat mass percentage at 6 months6 monthsVariation between Visit 1 (baseline) and Visit 4 (end of the intervention). Fat mass percentage (%FM) assessed using bioelectrical impedance analysis with InBody 270®.
Fat-free mass index at 6 months6 monthsVariation between Visit 1 (baseline) and Visit 4 (end of the intervention). FFMI (kg/ m2) calculated using FFM (in kilograms) and height (in meters).
BMI z-score at 6 months6 monthsVariation between Visit 1 (baseline) and Visit 4 (end of the intervention). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2. Then, BMI z-score will be calculated by WHO Anthroplus software 3.2.2.
BMI at 6 months6 monthsVariation between Visit 1 (baseline) and Visit 4 (end of the intervention). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2.

Secondary

MeasureTime frameDescription
Participants achieving a BMI reduction ≥10%6 months and 12 monthsPercentage of participants achieving a BMI reduction ≥10% between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Fat-free mass index at 12 months12 monthsVariation between Visit 1 (baseline) and Visit 6 (end of the follow-up). FFMI (kg/ m2) calculated using FFM (in kilograms) and height (in meters).
BMI z-score at 12 months12 monthsVariation between Visit 1 (baseline) and Visit 6 (end of the follow-up). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2. Then, BMI z-score will be calculated by WHO Anthroplus software 3.2.2.
BMI at 12 months12 monthsVariation between Visit 1 (baseline) and Visit 6 (end of the follow-up). Weight (in kilograms) and height (in meters) will be used to calculate BMI in kg/m2.
Change in Waist-to-height Ratio6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Change in C-reactive protein6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Change in Fasting Lipid: Total Cholesterol6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Change in Fasting Lipid: LDL-cholesterol6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Change in Fasting Lipid: HDL-cholesterol6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Change in Fasting Lipid: Triglycerides6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Change in centiles of Systolic and Diastolic Blood Pressure6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6. Blood pressure measured and centiles according to the American Academy of Pediatrics.
Change in HbA1c6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6.
Change in HOMA-B6 months and 12 monthsVariation between Visit 1 and Visit 4 and between Visit and Visit 6. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).
Change in HOMA-IR6 months and 12 monthsVariation between Visit 1 and Visit 4 and between Visit and Visit 6. HOMA-IR was calculated as: Insulin resistance (%) = fasting insulin \[mU/L\] x FPG \[mmol/L\]/ 22.5. R
Change in Continuous metabolic syndrome score6 months and 12 monthsVariation between Visit 1 and Visit 4 and between Visit and Visit 6. Calculation according to Vukovic R, et al. PLoS One. 2017 Dec 6;12(12):e0189232.
Change in Sleep quality6 months and 12 monthsSleep quality assessed by the Pittsburgh Sleep Quality Index, at Visit 1and Visit 4, and at Visit 6.
Change in sleep quality - actigrafy6 monthsSleep quality assessed by actigraphy and sleep diary, at Visit 1and Visit 4.
Change in Respiratory Sleep disorder6 monthsRespiratory sleep disorder assessed by the Pediatric sleep questionnaire at Visit 1and Visit 4.
Change in Diet Quality6 monthsMediterranean Diet Quality assessed with KIDMED questionnaire, at Visit 1 and Visit 4.
Change in Eating behavior6 monthsMEating behavior assessed with Eating Attitudes Test questionnaire, at Visit 1 and Visit 4.
Change in emotional well-being6 monthsAt Visit 1 and Visit 4: Emotional well-being assessed through the WHO-5.
Change in Quality of life6 monthsAt Visit 1 and Visit 4: Quality of life evaluated with the KIDSCREEN 52 questionnaire.
Change in self-compassion6 monthsAt Visit 1 and Visit 4: Self-compassion evaluated with the Self-Compassion Scale for adolescents.
Change in Physical activity6 monthsPhysical activity assessed with International Physical Activity Questionnaire for Adolescents, at Visit 1 and Visit 4.
Change in Physical activity - actigraphy6 monthsPhysical activity assessed by actigraphy, at Visit 1 and Visit 4.
Change in Glycaemic Category6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6. Number of participants in glycaemic categories, normoglycaemia, pre-diabetes and type 2 diabetes (T2DM) 2 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: fasting plasma glucose (FPG) \<100 mg/dL and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes (T2DM): FPG ≥126 mg/dL and/or HbA1c ≥6.5%
Change in Waist circumference centile6 months and 12 monthsVariation between Visit 1 and Visit 4, and between Visit 1 and Visit 6. waist circumference in centimeters, and centiles according to Sharma AK, et al. Pediatr Res. 2015.
Fat mass percentage at 12 months12 monthsVariation between Visit 1 (baseline) and Visit 6 (end of the follow-up). Fat mass percentage (%FM) assessed using bioelectrical impedance analysis with InBody 270®.
Participants achieving a BMI reduction ≥5%6 months and 12 monthsPercentage of participants achieving a BMI reduction ≥5% between Visit 1 and Visit 4, and between Visit 1 and Visit 6.

Other

MeasureTime frameDescription
Tryptophan pathway metabolites measurement6 monthsLevels of tryptophan, kynurenine, serotonin, and melatonin in plasma samples, by metabolomic analysis/ liquid chromatography, at baseline (Visit 1) and after the Intervention (Visit 4).
Leptin and ghrelin levels6 monthsLevels of leptin and ghrelin will be measured in plasma samples using enzyme-linked immunosorbent assay (ELISA) at baseline (Visit 1) and after the intervention (Visit 4).

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026